NYSE:SYK

Stryker Competitors

$271.81
+0.87 (+0.32 %)
(As of 08/2/2021 11:50 AM ET)
Add
Compare
Today's Range
$271.37
$273.54
50-Day Range
$248.90
$270.94
52-Week Range
$185.20
$275.15
Volume14,722 shs
Average Volume1.17 million shs
Market Capitalization$102.50 billion
P/E Ratio49.78
Dividend Yield0.93%
Beta0.98

Stryker (NYSE:SYK) Vs. ABT, MDT, ISRG, BDX, EW, and BSX

Should you be buying SYK stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Stryker, including Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), and Boston Scientific (BSX).

Abbott Laboratories (NYSE:ABT) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Dividends

Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 0.9%. Abbott Laboratories pays out 49.3% of its earnings in the form of a dividend. Stryker pays out 33.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has increased its dividend for 49 consecutive years and Stryker has increased its dividend for 1 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

73.0% of Abbott Laboratories shares are held by institutional investors. Comparatively, 72.3% of Stryker shares are held by institutional investors. 1.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 6.7% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Abbott Laboratories and Stryker's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$34.61 billion6.22$4.50 billion$3.6533.19
Stryker$14.35 billion7.14$1.60 billion$7.4336.58

Abbott Laboratories has higher revenue and earnings than Stryker. Abbott Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Abbott Laboratories and Stryker, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories121302.75
Stryker171502.61

Abbott Laboratories currently has a consensus target price of $124.6667, suggesting a potential upside of 2.62%. Stryker has a consensus target price of $283.8636, suggesting a potential upside of 3.99%. Given Stryker's higher probable upside, analysts clearly believe Stryker is more favorable than Abbott Laboratories.

Profitability

This table compares Abbott Laboratories and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories15.85%27.00%12.39%
Stryker12.82%26.08%10.41%

Risk and Volatility

Abbott Laboratories has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Stryker on 9 of the 17 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Dividends

Medtronic pays an annual dividend of $2.52 per share and has a dividend yield of 1.9%. Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 0.9%. Stryker pays out 33.9% of its earnings in the form of a dividend. Medtronic has raised its dividend for 44 consecutive years and Stryker has raised its dividend for 1 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

79.5% of Medtronic shares are owned by institutional investors. Comparatively, 72.3% of Stryker shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 6.7% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Medtronic and Stryker's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$30.12 billion5.89$3.61 billionN/AN/A
Stryker$14.35 billion7.14$1.60 billion$7.4336.58

Medtronic has higher revenue and earnings than Stryker.

Analyst Ratings

This is a summary of recent recommendations for Medtronic and Stryker, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic041802.82
Stryker171502.61

Medtronic currently has a consensus target price of $135.1364, suggesting a potential upside of 2.32%. Stryker has a consensus target price of $283.8636, suggesting a potential upside of 3.99%. Given Stryker's higher probable upside, analysts clearly believe Stryker is more favorable than Medtronic.

Profitability

This table compares Medtronic and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic11.98%11.82%6.32%
Stryker12.82%26.08%10.41%

Risk & Volatility

Medtronic has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Intuitive Surgical (NASDAQ:ISRG) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

83.7% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 72.3% of Stryker shares are owned by institutional investors. 0.9% of Intuitive Surgical shares are owned by company insiders. Comparatively, 6.7% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Intuitive Surgical and Stryker's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.36 billion27.12$1.06 billion$8.82112.86
Stryker$14.35 billion7.14$1.60 billion$7.4336.58

Stryker has higher revenue and earnings than Intuitive Surgical. Stryker is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Intuitive Surgical and Stryker, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical09902.50
Stryker171502.61

Intuitive Surgical currently has a consensus target price of $939.3529, suggesting a potential downside of 5.85%. Stryker has a consensus target price of $283.8636, suggesting a potential upside of 3.99%. Given Stryker's stronger consensus rating and higher probable upside, analysts clearly believe Stryker is more favorable than Intuitive Surgical.

Profitability

This table compares Intuitive Surgical and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical31.43%16.18%14.23%
Stryker12.82%26.08%10.41%

Risk & Volatility

Intuitive Surgical has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Becton, Dickinson and (NYSE:BDX) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Becton, Dickinson and and Stryker, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and05402.44
Stryker171502.61

Becton, Dickinson and currently has a consensus target price of $276.75, suggesting a potential upside of 7.97%. Stryker has a consensus target price of $283.8636, suggesting a potential upside of 3.99%. Given Becton, Dickinson and's higher probable upside, equities research analysts clearly believe Becton, Dickinson and is more favorable than Stryker.

Profitability

This table compares Becton, Dickinson and and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and8.98%15.53%6.94%
Stryker12.82%26.08%10.41%

Institutional & Insider Ownership

83.3% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 72.3% of Stryker shares are owned by institutional investors. 0.8% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 6.7% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dividends

Becton, Dickinson and pays an annual dividend of $3.32 per share and has a dividend yield of 1.3%. Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 0.9%. Becton, Dickinson and pays out 32.5% of its earnings in the form of a dividend. Stryker pays out 33.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Becton, Dickinson and has raised its dividend for 50 consecutive years and Stryker has raised its dividend for 1 consecutive years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Risk & Volatility

Becton, Dickinson and has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Valuation & Earnings

This table compares Becton, Dickinson and and Stryker's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion4.35$874 million$10.2025.09
Stryker$14.35 billion7.14$1.60 billion$7.4336.58

Stryker has lower revenue, but higher earnings than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Summary

Stryker beats Becton, Dickinson and on 10 of the 17 factors compared between the two stocks.

Stryker (NYSE:SYK) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Stryker and Edwards Lifesciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker171502.61
Edwards Lifesciences151202.61

Stryker currently has a consensus price target of $283.8636, suggesting a potential upside of 3.99%. Edwards Lifesciences has a consensus price target of $119.3333, suggesting a potential upside of 5.09%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Stryker.

Profitability

This table compares Stryker and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker12.82%26.08%10.41%
Edwards Lifesciences29.69%29.73%19.10%

Institutional & Insider Ownership

72.3% of Stryker shares are owned by institutional investors. Comparatively, 80.3% of Edwards Lifesciences shares are owned by institutional investors. 6.7% of Stryker shares are owned by insiders. Comparatively, 1.4% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Stryker has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Valuation and Earnings

This table compares Stryker and Edwards Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.35 billion7.14$1.60 billion$7.4336.58
Edwards Lifesciences$4.39 billion16.10$823.40 million$1.8661.08

Stryker has higher revenue and earnings than Edwards Lifesciences. Stryker is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Summary

Edwards Lifesciences beats Stryker on 8 of the 14 factors compared between the two stocks.

Stryker (NYSE:SYK) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Stryker and Boston Scientific, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker171502.61
Boston Scientific031112.87

Stryker currently has a consensus price target of $283.8636, suggesting a potential upside of 3.99%. Boston Scientific has a consensus price target of $48.91, suggesting a potential upside of 6.00%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Stryker.

Profitability

This table compares Stryker and Boston Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker12.82%26.08%10.41%
Boston Scientific4.56%12.76%6.43%

Institutional & Insider Ownership

72.3% of Stryker shares are owned by institutional investors. Comparatively, 89.6% of Boston Scientific shares are owned by institutional investors. 6.7% of Stryker shares are owned by insiders. Comparatively, 0.7% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Stryker has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.

Valuation and Earnings

This table compares Stryker and Boston Scientific's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.35 billion7.14$1.60 billion$7.4336.58
Boston Scientific$9.91 billion6.59$-82,000,000.00$0.9647.93

Stryker has higher revenue and earnings than Boston Scientific. Stryker is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Stryker beats Boston Scientific on 10 of the 15 factors compared between the two stocks.


Stryker Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.9$121.16+0.1%$215.28 billion$34.61 billion34.13Insider Selling
Short Interest Decrease
Medtronic logo
MDT
Medtronic
2.9$132.01+0.5%$177.41 billion$30.12 billion49.63Short Interest Increase
Intuitive Surgical logo
ISRG
Intuitive Surgical
2.1$995.46+0.4%$118.21 billion$4.36 billion74.40
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.6$255.94+0.1%$74.43 billion$17.12 billion45.54Upcoming Earnings
Dividend Announcement
Edwards Lifesciences logo
EW
Edwards Lifesciences
2.2$113.60+1.2%$70.62 billion$4.39 billion48.76Earnings Announcement
Analyst Report
Short Interest Increase
Analyst Revision
Boston Scientific logo
BSX
Boston Scientific
2.3$46.01+0.9%$65.38 billion$9.91 billion139.43Earnings Announcement
Analyst Downgrade
Analyst Revision
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
2.0$682.19+0.5%$58.18 billion$2.71 billion81.31Earnings Announcement
Analyst Report
Analyst Revision
DexCom logo
DXCM
DexCom
2.4$510.74+0.9%$49.39 billion$1.93 billion97.28Earnings Announcement
Analyst Report
Analyst Revision
ResMed logo
RMD
ResMed
2.2$269.61+0.8%$39.23 billion$2.96 billion86.14Upcoming Earnings
Analyst Downgrade
Analyst Revision
Baxter International logo
BAX
Baxter International
2.6$77.16+0.2%$38.80 billion$11.67 billion35.23Earnings Announcement
Analyst Report
Analyst Revision
Hologic logo
HOLX
Hologic
2.4$75.82+1.0%$19.22 billion$3.78 billion9.72Earnings Announcement
Analyst Report
Analyst Revision
STERIS logo
STE
STERIS
2.5$219.05+0.5%$18.70 billion$3.11 billion47.52Upcoming Earnings
Insulet logo
PODD
Insulet
1.9$280.21+0.2%$18.57 billion$904.40 million2,155.46Upcoming Earnings
Teleflex logo
TFX
Teleflex
2.4$395.29+0.5%$18.47 billion$2.54 billion53.35Earnings Announcement
Dividend Announcement
Analyst Report
Short Interest Increase
Analyst Revision
Masimo logo
MASI
Masimo
1.9$275.23+1.0%$15.15 billion$1.14 billion71.30Earnings Announcement
Analyst Revision
Abiomed logo
ABMD
Abiomed
2.0$330.07+0.9%$14.97 billion$847.52 million66.95Upcoming Earnings
Hill-Rom logo
HRC
Hill-Rom
2.1$138.25+0.2%$9.19 billion$2.88 billion38.94Earnings Announcement
Analyst Report
Insider Selling
Globus Medical logo
GMED
Globus Medical
2.3$83.18+0.0%$8.35 billion$789.04 million69.90Upcoming Earnings
Integra LifeSciences logo
IART
Integra LifeSciences
1.8$72.28+0.2%$6.11 billion$1.37 billion29.99Earnings Announcement
Analyst Revision
AtriCure logo
ATRC
AtriCure
1.9$85.13+0.8%$3.88 billion$206.53 million-76.69Upcoming Earnings
Insider Selling
NuVasive logo
NUVA
NuVasive
1.7$62.75+1.9%$3.24 billion$1.05 billion3,139.07Earnings Announcement
Analyst Revision
Integer logo
ITGR
Integer
2.0$96.87+1.1%$3.19 billion$1.07 billion33.06Earnings Announcement
Analyst Report
Analyst Revision
Cardiovascular Systems logo
CSII
Cardiovascular Systems
2.2$38.72+4.1%$1.56 billion$236.54 million-61.46Upcoming Earnings
Short Interest Increase
Alphatec logo
ATEC
Alphatec
2.0$15.10+2.4%$1.47 billion$144.86 million-13.73Upcoming Earnings
CryoLife logo
CRY
CryoLife
2.0$27.15+0.6%$1.06 billion$253.23 million-87.58Earnings Announcement
Analyst Report
Analyst Revision
AngioDynamics logo
ANGO
AngioDynamics
2.0$26.95+1.2%$1.04 billion$291.01 million-32.87
Orthofix Medical logo
OFIX
Orthofix Medical
1.7$40.14+1.0%$785.10 million$406.56 million-26.76Upcoming Earnings
Short Interest Increase
Surmodics logo
SRDX
Surmodics
2.3$56.11+1.8%$778.13 million$94.86 million107.91Upcoming Earnings
Accuray logo
ARAY
Accuray
2.3$4.13+0.7%$385.17 million$382.93 million103.28
Invacare logo
IVC
Invacare
1.3$7.17+0.8%$250.63 million$850.69 million-5.74Upcoming Earnings
Rockwell Medical logo
RMTI
Rockwell Medical
1.7$0.73+0.7%$68.81 million$62.20 million-1.99
This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.